Chekalina, N.Shlykova, O.Mykytiuk, M.Izmailova, O.Vesnina, L.Kazakov, Yu.Kaidashev, I. P.Кайдашев, Ігор ПетровичЧекаліна, Наталія ІгорівнаШликова, Оксана АнатоліївнаМикитюк, Марина ВолодимирівнаІзмайлова, Ольга ВіталіївнаВесніна, Людмила ЕдуардівнаКазаков, Юрій Михайлович2017-10-172017-10-172016-11Resveratrol reduces the level of chronic systemic inflammation in stable coronary artery disease / N. I. Chekalina, O. A. Shlykova, M. V. Mykytiuk [et al.] // Integr Food Nutr Metab. – 2016. – № 4. – С. 1–4.2056-8339https://repository.pdmu.edu.ua/handle/123456789/1126This study aimed to investigate the effects of plant polyphenol of resveratrol on chronic systemic inflammation indicators of stable coronary artery disease. 85 patients with coronary heart disease were recruited and prescribed a standard therapy (β-blockers, statins, aspirin). 30 patients received resveratrol at a dose of 100 mg daily and the other serves as the control group. Cytokines and the expression of mRNA gene of inhibitor of kappa B α (IkBα) of nuclear factor of transcription kappa B (NF-kB) were determined. The results show that patients with coronary artery disease exhibited increased levels of interleukin-1β (IL-1β), tumor necrosis factor (TNFα), and IL-10 in the blood. Resveratrol treatment led to a reliable reduction IL-1β and TNFα, the content of IL-10 tended to reduce. In addition, we failed to notice any significant difference in the inhibitor of kappa B α (IkBα) of nuclear factor of transcription kappa B between groups. In conclusion, in patients with coronary artery disease, resveratrol shows anti-inflammatory properties via reducing the content of proinflammatory cytokines in the blood, such as IL-1β and TNFα.encoronary heart diseaseresveratrolchronic systemic inflammationinflammatory signaling cascadesArticle